Takeda Calls Off PIII Study of Sakigake-Designated Ninlaro for AL Amyloidosis after Failing to Hit Primary Goal

Takeda Pharmaceutical said on June 6 that it will pull the plug on a multinational PIII clinical study of its multiple myeloma drug Ninlaro (ixazomib) in patients with relapsed/refractory systemic light-chain (AL) amyloidosis. The PIII TOURMALINE-AL1 study evaluated the improvement...read more